Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Stock Information for GeoVax Labs Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About GeoVax Labs Inc.

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ(TM) in Leptomeningeal Metastases
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ(TM) in Leptomeningeal Metastases
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET
Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.